Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ICG-001 + Verteporfin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ICG-001 | ICG001|ICG 001 | CTNNB1 Inhibitor 27 | ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234, PMID: 29332125, PMID: 32642722). | |
| Verteporfin | Visudyne | YAP Inhibitor 3 | Visudyne (verteporfin) is a small molecule that binds to YAP1 and inhibits the interaction between YAP1 and TEAD, potentially resulting in decreased growth of YAP-driven tumor cells (PMID: 22677547, PMID: 28576749). Verteporfin is FDA-approved for treatment of age-related macular degeneration (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|